Cronos Group Inc.

What they do

Cronos operates one wholly owned licensed producer in Canada, Peace Naturals Project Inc., with facilities at its Peace Naturals Campus in Stayner, Ontario, and consolidates Cronos GrowCo, in which it holds a 50% equity interest and which is its principal source of cannabis. It holds IMC-GAP, IMC-GMP and IMC-GDP certifications for medical cannabis cultivation, production, distribution and marketing in Israel. It also distributes PEACE NATURALS, LIT and white-labeled products to select international markets. The company reports through a single consolidated segment covering both Canada and Israel.

Revenue drivers

• Israel medical cannabis (PEACE NATURALS) — Cronos said in its August 2026 release that Israel delivered its tenth consecutive quarter of record net revenue and that PEACE NATURALS remains the leading cannabis brand there, based on pharmacy data it collects.
• Canada recreational cannabis (Spinach) — The release states Q2 2026 delivered record net revenue in Canada, with Spinach maintaining #1 share in vapes for a second consecutive quarter and in edibles for an eighth consecutive quarter, per Hifyre retail data; management also cited gains in pre-rolls and flower.
• International markets outside Canada and Israel — The company reported record net revenue outside Canada and Israel in Q2 2026, led by demand for PEACE NATURALS in Germany, where it distributes branded and white-labeled products.

Recent performance

For the quarter ended June 30, 2026, net revenue was $53.0 million versus $33.5 million a year earlier, an increase of 58%, and six-month revenue was $98.2 million versus $65.7 million. Gross profit was $28.5 million in Q2 2026 with a 54% gross margin, compared with $14.5 million and 43% a year earlier. Net income was $35.7 million in the quarter versus a $38.5 million loss in the prior-year period. Adjusted EBITDA was $13.1 million in Q2 2026 versus $1.7 million, and $18.2 million for the first half of 2026 versus $4.0 million. The company said Q2 2026 net revenue rose 51% year-over-year on an organic, constant-currency basis.

Strategy

Cronos states four core priorities: growing a portfolio of iconic brands, developing a diversified global sales and distribution network, establishing an efficient global supply chain, and creating and monetizing disruptive intellectual property. It is expanding internationally by distributing PEACE NATURALS and LIT and white-labeled products into new markets, and closed and is integrating the acquisition of CanAdelaar B.V. It also entered a transaction giving it majority control of Cronos GrowCo's board and a junior secured convertible loan to High Tide with a warrant. The company has been active on capital return, repurchasing 12.3 million shares in the first half of 2026 under a program renewed May 8, 2026. Management frames the roughly $467 million in cash and equivalents plus $330 million of short-term investments as support for growth investment and further returns of capital.

Risks

• Israel anti-dumping exposure — Cronos faces an anti-dumping investigation by Israel's Trade Levies Commissioner into alleged dumping of Canadian medical cannabis imports, and any duty imposed could affect its ability to import and sell in Israel, its record-revenue market.
• Middle East conflict — The company flags the Middle East Conflict and potential regional escalation as a risk to its employees, facilities and operations in Israel, and to product supply and patient demand there.
• Profitability and history of losses — Cronos reported net losses in 2021, 2022, 2023 and again in 2025 ($2.9 million), and its risk factors state it may not achieve or maintain profitability or may continue to incur losses.
• Acquisition and write-down risk — The risk factors note the acquisition strategy may not succeed, that Cronos may not complete or realize expected benefits from the CanAdelaar acquisition, and that it has previously written down goodwill and intangible assets from acquisitions.

Outlook

Management said the company is well positioned to invest in its growth strategy while returning capital to shareholders and keeping optionality for opportunities, citing positive cash flow from operations and what it calls an industry-leading balance sheet. Stated expectations cover continued growth in markets outside Canada and Israel, expansion of the Peace Naturals Campus, and the potential benefits of the Cronos GrowCo and CanAdelaar transactions. No specific revenue or earnings guidance figures were provided in the excerpts reviewed.